Indications & formulation #
Moderate-to-severe Alzheimer dementia. This reference covers the selected formulation; other indications and products need their own evidence.
Dose reference #
Adult educational reference · Oral solution 2 mg/mL · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.
Start 5 mg/day; increase by 5 mg no more often than weekly toward 20 mg/day in two doses. Verify concentration and measuring device.
Contraindications & important cautions #
Hypersensitivity is a contraindication. Review dizziness/confusion and factors alkalinizing urine or other NMDA-active drugs.
Selected important cautions; consult the full product information for all contraindications and warnings.
Adverse effects #
Dizziness, headache, confusion and constipation can affect daily function.
Interactions #
Renal function affects prescribing; review other NMDA-active drugs and factors altering renal elimination.
Monitoring #
Review renal context, tolerability, function and caregiver observations for the specific dementia indication.
Special populations #
Severe renal impairment (CrCl 5–29): target 5 mg twice daily. Use caution in severe hepatic impairment.
Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.
Discontinuation, restarting & counseling #
After several missed days, a lower restart and retitration may be needed. Review function and caregiver observations.
Condition-specific prescribing #
Additional indication-specific records retain their own formulation and source context.
Memantine
Moderate–severe Alzheimer dementia
Adults · Immediate-release tablet · Oral · US label; UK NICE treatment positioning
- Starting dose
- 5 mg once daily.
- Titration
- At intervals of at least 1 week: 5 mg twice daily, then 5 mg morning/10 mg evening, then 10 mg twice daily.
- Treatment range / target
- Target 20 mg/day in divided doses when tolerated.
- Maximum / limits
- 20 mg/day for this formulation; severe renal impairment target 10 mg/day.
- Trial & duration
- Reassess continuing clinical usefulness; after several missed days, lower-dose restarting and retitration may be required.
- Monitoring
- Renal function, dizziness, confusion, constipation and functional response.
- Population & organ-function adjustments
- Creatinine clearance 5–29 mL/min: target 5 mg twice daily. Use caution in severe hepatic impairment.
- Important cautions
- Urine alkalinization can reduce clearance. Check other NMDA antagonists. Do not double a missed dose.
Brands & products #
Historical catalogue observations. Prices and catalogue presence do not establish current availability or Indian approval.
Reference coverage #
Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.
References · 3
- Memantine — Oral solution 2 mg/mL — selected prescribing information · United States · Checked 2026-10-27 · Selected formulation: Oral solution 2 mg/mL · Supports indications, dose, cautions, adverse effects, interactions, monitoring, special populations and stopping. Source sections: Indications and usage; Dosage and administration; Contraindications; warnings and precautions; Use in specific populations; patient counseling
- DailyMed: Memantine immediate-release tablets · United States label · Checked 2026-10-26 · Supports: Memantine — Moderate–severe Alzheimer dementia (Immediate-release tablet)
- NICE NG97: Dementia recommendations · United Kingdom · Checked 2026-10-26 · Supports: Memantine — Moderate–severe Alzheimer dementia (Immediate-release tablet)